Sarepta Therapeutics (NASDAQ: SRPT) reported Q1 EPS of ($3.42), $5.38 worse than the analyst estimate of $1.96. Revenue for the quarter came in at $774.9 million versus the consensus estimate of $695.9 million.

GUIDANCE:

Sarepta Therapeutics sees FY2025 revenue of $2.3-2.6 billion, versus the consensus of $3.07 billion.

2025 Financial Guidance

	Updated Guidance	Prior Guidance	Assumptions
	As of May 6, 2025	As of February 26, 2025
Total net product revenues	$2,300 - $2,600M	$2,900 - $3,100M	Reflects updated ELEVIDYS outlook Represents +37% YoY growth at the midpoint of the revised range
Combined non-GAAP R&D and SG&A expenses	$1,784 - $2,184M	$1,200 - $1,300M	Consistent operating expense outlook from prior guidance, now includes Arrowhead collaboration: Closing transaction costs ($584M) Potential DM1 development milestone payments ($100-$300M)

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.